Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigation through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Treatment Options in Multiple Myeloma
Oncology nurses should understand the evolving therapeutic options available and the side effects related to those treatments as well as the current guidelines in the context of the patient's previous therapy and disease history to navigate the various options available.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
A uniform treatment approach cannot be applied to all patients with multiple myeloma (MM). Clinicians must understand when to administer two-, three- or four or more drug regimens taking into consideration disease- and patient- characteristics. Illustrating how to individualize treatment plans will help educate health care providers about how to make best decisions in their own practice and improve outcomes of patients with newly diagnosed MM.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
Clinicians face a difficult task of deciding who to treat, when to treat, and how to treat especially since many factors need to considered when determining the optimal multiple myeloma (MM) treatment for relapsed/refractory MM including: age, prognostic factors, comorbidities, toxicity profiles,
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Update: Multiple Myeloma
Clinicians must understand the evolving therapeutic options and guidelines for administration of the available therapies in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Multiple Myeloma, Version 3.2022
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma.
Category
  • Multiple Myeloma
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation